The Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer

ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-80
SponsorYunnan Cancer Hospital

About this trial

We consecutively enrolled patients presenting with breast space-occupying lesions at our hospital. Medical imaging data from simultaneously acquired ultrafast DCE-MRI, time-dependent diffusion MRI (TDD-MRI), magnetic resonance elastography (MRE), andvirtual magnetic resonance elastography(vMRE), along with clinical and pathological data, were collected. The study aims to evaluate and explore the clinical application value of these multimodal imaging techniques in the precision diagnosis, treatment, and prognosis of breast cancer. The findings are intended to provide a robust imaging basis for formulating and adjusting more precise, individualized treatment plans and prognostic assessments for patients. Ultimately, this research seeks to improve patient quality of life, optimize the allocation of medical resources, and advance the development of precision medicine.

Eligibility criteria

Qualifiers

Age ≥ 18 years old

Female patients with BI-RADS class 4 or above breast lesions detected by mammography or ultrasound

Perform breast new technology MRI examination (ultra fast DCE-MRI、OGSE 、MRE、vMRE)within one week before biopsy or surgery

Disqualifiers

Previously received breast radiotherapy, chemotherapy, surgery, or targeted therapy

Unable to cooperate in completing MRI examination

The image data contains serious artifacts (such as motion artifacts and metal artifacts), making it impossible to measure parameters

The lesion cannot be clearly identified and outlined on the image

Trial design

Treatments tested in this trial

  • The Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators